Navigation Links
Where do you start when developing a new medicine?
Date:3/26/2014

ch of the three founding organisations and a multi-million pound contribution by GSK to fund an initial wave of projects.

Comments by the founding organisations:

Professor Patrick Vallance, President of Pharmaceuticals R&D at GSK, says: "Target validation is one of the greatest challenges in drug discovery. We need to understand better the mechanisms in our body related to disease to improve how we can develop the most effective medicines. By changing our business model, taking a more open-minded approach to sharing information and forging collaborations like the Centre for Therapeutic Target Validation, we believe there is an opportunity to accelerate the development of innovative new medicines. The UK leads the fields of genome sequencing and bioinformatics and I am delighted that GSK has the opportunity to collaborate here with two of its premier research institutions."

Professor Sir Mike Stratton, Director of the Wellcome Trust Sanger Institute, says: "Advances in genomics have led to a rapid increase in the availability of drug targets, providing enormous opportunity but also posing the problem of how we best convert this new knowledge into medicines. The challenge we now address is to identify those new targets with the greatest relevance to human disease which, in turn, will undoubtedly increase the speed and efficiency in which new medicines can be developed."

Professor Dame Janet Thornton, Director of the European Bioinformatics Institute, says: "Maximising our use of 'big data' in the life sciences is critical for solving some of society's most pressing problems. This collaboration gives us an opportunity to translate this complex information into biomedical discoveries. As biology becomes increasingly data-driven, pre-competitive collaborations such as the Centre for Therapeutic Target Validation have become crucial for improving efficiencies, driving down costs and providing the best opportunities to
'/>"/>

Contact: EMBL Press Office
pressoffice@embl.de
44-078-813-77941
European Molecular Biology Laboratory
Source:Eurekalert  

Page: 1 2 3 4

Related biology news :

1. Targeting enforcement where needed most in Africas heart of biodiversity
2. Where have all the codfish gone?
3. Dating is refined for the Atapuerca site where Homo antecessor appeared
4. Where do lizards in Qatar live? First distribution maps for the state
5. Tiny swimming bio-bots boldly go where no bot has swum before
6. Study shows Where Alzheimers starts and how it spreads
7. Big data project reveals where carbon-stocking projects in Africa provide the greatest benefits
8. High-resolution 3-D imaging draws new picture of Golgis whereabouts during cell division
9. Where water is limited, researchers determine how much water is enough
10. 2-way traffic enable proteins to get where needed, avoid disease
11. Deletion of any single gene provokes mutations elsewhere in the genome
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Where do you start when developing a new medicine?
(Date:3/20/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/rswjb4/hand_geometry ) has announced ... Business Report" report to their offering. This ... Thousands. The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... Annual estimates and forecasts are provided for the ...
(Date:3/19/2015)... March 19, 2015  NXT-ID, Inc. (NASDAQ: NXTD ... on the growing mobile commerce market, announces its biometric payment ... clip that aired this week on Washington DC,s ... In a segment "The Next Great Thing", host ... way to pay, and ,a really big breakthrough in mobile ...
(Date:3/17/2015)... March 17, 2015 Emotient, the leader ... today announced general availability of Emotient Analytics ... the analysis of facial expressions. The system analyzes ... content, products and services. It delivers audience response ... sentiment - as derived from facial evidence of ...
Breaking Biology News(10 mins):Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 2New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 4
... Fluctuations in penguin populations in the Antarctic are linked more ... to changes in their habitats, according to a new study ... Academy of Sciences . Funded in part by the Lenfest ... "winners" of changing conditions, such as large-scale ice melting, may ...
... NEW YORK (April 11, 2011) -- Weill Cornell Medical ... Surgeons have announced that The Mortimer D. Sackler, M.D. ... awarded to The Rockefeller University,s Dr. Fernando Nottebohm for ... the discovery of neuronal replacement. Dr. Nottebohm is ...
... FINDINGS: Certain differentiated cells in breast tissue can spontaneously ... researchers. Until now, scientific dogma has stated that differentiation ... return to the flexible stem-cell state on their own. ... well as for breast cancer cells. RELEVANCE: ...
Cached Biology News:Penguins that shun ice still lose big from a warming climate 2Sackler Prize awarded to pioneering neuroscientist 2Sackler Prize awarded to pioneering neuroscientist 3Scientists identify a surprising new source of cancer stem cells 2Scientists identify a surprising new source of cancer stem cells 3
(Date:4/23/2015)... WuXi PharmaTech (Cayman) Inc. (NYSE: WX ... company serving the pharmaceutical, biotechnology and medical device industries, ... the United States , today announced ... quarter of 2015 after the New York Stock Exchange ... Thursday morning, May 14, 2015 Shanghai time). The earnings ...
(Date:4/23/2015)... SOUTH SAN FRANCISCO, Calif. , April 23, 2015 /PRNewswire/ ... it has entered into a definitive agreement to sell ... private placement. Under the agreement, the investors will purchase ... a purchase price of $8.15 per share, the closing ... was led by new and existing investors, including Broadfin ...
(Date:4/23/2015)... April 23, 2015 Proove ... Personalized Medicine, is excited to announce the launch ... . This profile assesses 62 genetic variations to ... information for commonly prescribed non-opioid pain medications, namely ... Neurontin), alprazolam (brand name Xanax) and acetaminophen (brand ...
(Date:4/23/2015)... 2015 /PRNewswire/ - Crystal Research Associates, LLC announced today ... (EIO) on Aeterna Zentaris Inc. (NASDAQ: AEZS ... Crystal Research Associates, website at www.crystalra.com ... www.aezsinc.com . Aeterna Zentaris ("Aeterna" or ... in oncology, endocrinology, and women,s health. With a focus ...
Breaking Biology Technology:WuXi PharmaTech Schedules First-Quarter 2015 Earnings Release 2WuXi PharmaTech Schedules First-Quarter 2015 Earnings Release 3Veracyte, Inc. Announces $40 Million Private Placement 2Veracyte, Inc. Announces $40 Million Private Placement 3Veracyte, Inc. Announces $40 Million Private Placement 4Proove Biosciences Launches World’s First Test to Predict Responders to Commonly Prescribed Non-Opioid Pain Medications 2Proove Biosciences Launches World’s First Test to Predict Responders to Commonly Prescribed Non-Opioid Pain Medications 3Crystal Research Associates, LLC Issues Executive Informational Overview (EIO) on Aeterna Zentaris Inc. 2Crystal Research Associates, LLC Issues Executive Informational Overview (EIO) on Aeterna Zentaris Inc. 3
... 28 Boston,Scientific Corporation (NYSE: BSX ) ... that Boston Scientific has completed its acquisition of ... April 16.,Under the terms of the transaction, all ... per share in cash, for a total of,approximately ...
... N.J., May 28 National Stem Cell,Holding, Inc. (OTC: ... steps to,change its name to Proteonomix, Inc. The change ... Michael Cohen, President/CEO, stated: "Our new name reflects the ... development stage and,commencing the commercialization of our technologies. These ...
... Provides Additional Global Corporate Finance, Management and ... Manufacturing ... (TSX: NVN) announced today the appointment of Gordon H.,Busenbark to ... chief financial officer of Xytis Pharmaceuticals, a privately,held development-stage specialty ...
Cached Biology Technology:Boston Scientific Completes Acquisition of CryoCor 2Boston Scientific Completes Acquisition of CryoCor 3National Stem Cell Holding, Inc. Announces the Change of Its Name to Proteonomix, Inc. 2National Stem Cell Holding, Inc. Announces the Change of Its Name to Proteonomix, Inc. 3Nventa Appoints Gordon H. Busenbark to Board of Directors 2